-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Efineptakin Alfa in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Efineptakin Alfa in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Efineptakin Alfa in Non-Small Cell Lung Cancer Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Erenumab in Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Erenumab in Pain report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Erenumab in Pain Drug Details: Erenumab (Aimovig, Aerinex, Pasurta, Glaseeq) is a human immunoglobulin...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Iptacopan Hydrochloride in Age Related Macular Degeneration
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Iptacopan Hydrochloride in Age Related Macular Degeneration Drug Details: Iptacopan hydrochloride (Fabhalta) is a factor B...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mipasetamab Uzoptirine in Malignant Fibrous Histiocytoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mipasetamab Uzoptirine in Malignant Fibrous Histiocytoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mipasetamab Uzoptirine in Malignant Fibrous Histiocytoma Drug Details: ADCT-601(BGB-601)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zanidatamab in Extrahepatic Bile Duct Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Zanidatamab in Extrahepatic Bile Duct Cancer Drug Details: Zanidatamab is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MRTX-1133 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MRTX-1133 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MRTX-1133 in Non-Small Cell Lung Cancer Drug Details: MRTX1133 is...